Answers are grounded in this paper and cite their sources.
At Pfizer Central Research, high-throughput screening has been an important source of new leads for drug discovery for a decade. Our experience with over 150 high-throughput screens can address questions about necessary file size, how well particular biological targets fare (with particular reference to protein-protein interactions), and what file diversity means in practice.
No takes yet. Share an insight, caveat, or question.
Robin W. Spencer (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: